[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Standard Treatment (STns): 1.\tStrict Isolation2.\tStandard Precautions (Hand hygiene; Cough Etiquette; Wear surgical mask)3.\tHydration4.\tProper Nutrition5.\tSupportive Pharmacotherapy (Antipyretic; Antiallergic; Cough Suppressant)6.\tTreatment of Comorbid Diseases7.\tOseltamivir (75 mg BD) for patient who are tested positive for H1N1If the patient improves clinically the same treatment will be continued. If the patient do-not improve or shows sign of severity (mentioned above) the patient will be shifted to the severity arm (S-group) of the clinical trial with randomization again.Intervention2: Standard Treatment for severe patients: (STs): 1.\tStrict Isolation2.\tStandard Precautions (Hand hygiene; Cough Etiquette; Wear surgical mask)3.\tFluid Therapy 4.\tSupportive Pharmacotherapy (Antipyretic; Antiallergic; Cough Suppressant)5.\tOxygen supplementation (As required)6.\tInvasive ventilation (As required)7.\tAntibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients)8.\tVasopressor support9.\tRenal-replacement therapy10.\tTreatment of Comorbid Diseases11.\tOseltamivir (75 mg BD) for patient who are tested positive for H1N1Patients will be assessed for clinical improvement in every 48-72 hours of treatment. In case the patient do not respond to the current treatment regimen the patient will be shifted to alternative regimen in the same treatment group. If the patient progress in the same group then patient will be shifted to biologics (Tocilizumab). In case the patient do not respond in the next 48-72 hours and continue to deteriorate on the current treatment then the all experimental treatment will be stopped and Standard Treatment (STs) will be continued. Intervention3: Standard Treatment (", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1571, "treatment_name": "Hydroxychloroquine+ribavirin", "treatment_type": "Antimalarials+antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1694, "treatment_name": "Lopinavir+ribavirin+ritonavir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Standard Treatment (STns): 1.\tStrict Isolation2.\tStandard Precautions (Hand hygiene; Cough Etiquette; Wear surgical mask)3.\tHydration4.\tProper Nutrition5.\tSupportive Pharmacotherapy (Antipyretic; Antiallergic; Cough Suppressant)6.\tTreatment of Comorbid Diseases7.\tOseltamivir (75 mg BD) for patient who are tested positive for H1N1If the patient improves clinically the same treatment will be continued. If the patient do-not improve or shows sign of severity (mentioned above) the patient will be shifted to the severity arm (S-group) of the clinical trial with randomization again.Intervention2: Standard Treatment for severe patients: (STs): 1.\tStrict Isolation2.\tStandard Precautions (Hand hygiene; Cough Etiquette; Wear surgical mask)3.\tFluid Therapy 4.\tSupportive Pharmacotherapy (Antipyretic; Antiallergic; Cough Suppressant)5.\tOxygen supplementation (As required)6.\tInvasive ventilation (As required)7.\tAntibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients)8.\tVasopressor support9.\tRenal-replacement therapy10.\tTreatment of Comorbid Diseases11.\tOseltamivir (75 mg BD) for patient who are tested positive for H1N1Patients will be assessed for clinical improvement in every 48-72 hours of treatment. In case the patient do not respond to the current treatment regimen the patient will be shifted to alternative regimen in the same treatment group. If the patient progress in the same group then patient will be shifted to biologics (Tocilizumab). In case the patient do not respond in the next 48-72 hours and continue to deteriorate on the current treatment then the all experimental treatment will be stopped and Standard Treatment (STs) will be continued. Intervention3: Standard Treatment (", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]